Small Lymphocytic Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major small lymphocytic lymphoma markets are expected to exhibit a CAGR of 2.3% during 2024-2034.
The small lymphocytic lymphoma market has been comprehensively analyzed in IMARC's new report titled "Small Lymphocytic Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Small lymphocytic lymphoma refers to a type of non-Hodgkin lymphoma characterized by the abnormal proliferation of small mature B-lymphocytes in the lymph nodes and other organs. The condition can manifest with various symptoms, including painless swollen lymph nodes in the armpits, neck, or groin, unexplained fatigue, unintended weight loss, night sweats, recurrent infections, a feeling of fullness or discomfort in the abdomen, etc. The diagnosis of small lymphocytic lymphoma involves a combination of clinical evaluation, imaging studies, and pathological examination of lymph nodes or tissue biopsies. Initial assessment includes a thorough medical history, physical exam, and blood tests to evaluate the patient's overall health as well as detect any abnormalities. Various imaging techniques, such as computed tomography (CT) and positron emission tomography (PET) scans, are used to identify lymph node involvement and stage the disease. In order to confirm the diagnosis, a biopsy of an affected lymph node or other involved tissue is performed. Numerous additional tests, including flow cytometry, immunohistochemistry, genetic analysis, etc., are also conducted to determine specific markers and genetic alterations associated with the disease.
The increasing prevalence of certain genetic abnormalities, which can disrupt normal cell growth and regulation, leading to the accumulation of abnormal B-cells, is primarily driving the small lymphocytic lymphoma market. In addition to this, the rising incidence of several associated risk factors, such as familial predisposition, advancing age, immunodeficiency conditions like human immunodeficiency virus (HIV) infection, etc., is acting as another significant growth-inducing factor. Moreover, the widespread adoption of immune checkpoint inhibitors, including pembrolizumab and nivolumab, that aid in enhancing the body's immune system to recognize and attack cancer cells more effectively is further bolstering the market growth. Apart from this, the escalating application of targeted therapy, which involves the use of drugs that selectively target specific molecules or pathways involved in cancer cell growth and survival, is also creating a positive outlook for the market. Additionally, the emerging popularity of circulating tumor DNA (ctDNA) analysis, since it helps in monitoring disease burden, assessing treatment response, and detecting the emergence of resistance mutations, is expected to drive the small lymphocytic lymphoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the small lymphocytic lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for small lymphocytic lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the small lymphocytic lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the small lymphocytic lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the small lymphocytic lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current small lymphocytic lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the small lymphocytic lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the small lymphocytic lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the small lymphocytic lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of small lymphocytic lymphoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of small lymphocytic lymphoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of small lymphocytic lymphoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with small lymphocytic lymphoma across the seven major markets?
What is the size of the small lymphocytic lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of small lymphocytic lymphoma?
What will be the growth rate of patients across the seven major markets?
Small Lymphocytic Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for small lymphocytic lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the small lymphocytic lymphoma market?
What are the key regulatory events related to the small lymphocytic lymphoma market?
What is the structure of clinical trial landscape by status related to the small lymphocytic lymphoma market?
What is the structure of clinical trial landscape by phase related to the small lymphocytic lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the small lymphocytic lymphoma market?
The small lymphocytic lymphoma market has been comprehensively analyzed in IMARC's new report titled "Small Lymphocytic Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Small lymphocytic lymphoma refers to a type of non-Hodgkin lymphoma characterized by the abnormal proliferation of small mature B-lymphocytes in the lymph nodes and other organs. The condition can manifest with various symptoms, including painless swollen lymph nodes in the armpits, neck, or groin, unexplained fatigue, unintended weight loss, night sweats, recurrent infections, a feeling of fullness or discomfort in the abdomen, etc. The diagnosis of small lymphocytic lymphoma involves a combination of clinical evaluation, imaging studies, and pathological examination of lymph nodes or tissue biopsies. Initial assessment includes a thorough medical history, physical exam, and blood tests to evaluate the patient's overall health as well as detect any abnormalities. Various imaging techniques, such as computed tomography (CT) and positron emission tomography (PET) scans, are used to identify lymph node involvement and stage the disease. In order to confirm the diagnosis, a biopsy of an affected lymph node or other involved tissue is performed. Numerous additional tests, including flow cytometry, immunohistochemistry, genetic analysis, etc., are also conducted to determine specific markers and genetic alterations associated with the disease.
The increasing prevalence of certain genetic abnormalities, which can disrupt normal cell growth and regulation, leading to the accumulation of abnormal B-cells, is primarily driving the small lymphocytic lymphoma market. In addition to this, the rising incidence of several associated risk factors, such as familial predisposition, advancing age, immunodeficiency conditions like human immunodeficiency virus (HIV) infection, etc., is acting as another significant growth-inducing factor. Moreover, the widespread adoption of immune checkpoint inhibitors, including pembrolizumab and nivolumab, that aid in enhancing the body's immune system to recognize and attack cancer cells more effectively is further bolstering the market growth. Apart from this, the escalating application of targeted therapy, which involves the use of drugs that selectively target specific molecules or pathways involved in cancer cell growth and survival, is also creating a positive outlook for the market. Additionally, the emerging popularity of circulating tumor DNA (ctDNA) analysis, since it helps in monitoring disease burden, assessing treatment response, and detecting the emergence of resistance mutations, is expected to drive the small lymphocytic lymphoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the small lymphocytic lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for small lymphocytic lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the small lymphocytic lymphoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the small lymphocytic lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the small lymphocytic lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current small lymphocytic lymphoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the small lymphocytic lymphoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the small lymphocytic lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the small lymphocytic lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of small lymphocytic lymphoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of small lymphocytic lymphoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of small lymphocytic lymphoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with small lymphocytic lymphoma across the seven major markets?
What is the size of the small lymphocytic lymphoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of small lymphocytic lymphoma?
What will be the growth rate of patients across the seven major markets?
Small Lymphocytic Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for small lymphocytic lymphoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the small lymphocytic lymphoma market?
What are the key regulatory events related to the small lymphocytic lymphoma market?
What is the structure of clinical trial landscape by status related to the small lymphocytic lymphoma market?
What is the structure of clinical trial landscape by phase related to the small lymphocytic lymphoma market?
What is the structure of clinical trial landscape by route of administration related to the small lymphocytic lymphoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SMALL LYMPHOCYTIC LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SMALL LYMPHOCYTIC LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SMALL LYMPHOCYTIC LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SMALL LYMPHOCYTIC LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SMALL LYMPHOCYTIC LYMPHOMA - UNMET NEEDS
10 SMALL LYMPHOCYTIC LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 SMALL LYMPHOCYTIC LYMPHOMA - MARKETED PRODUCTS
11.1 List of Small Lymphocytic Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Imbruvica (Ibrutinib) - Janssen/Pharmacyclics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Calquence (Acalabrutinib) - Acerta Pharma/AstraZeneca
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Copiktra (Duvelisib) - Secura Bio
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Venclexta (Venetoclax) - AbbVie/Genentech
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Zydelig (Idelalisib) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SMALL LYMPHOCYTIC LYMPHOMA - PIPELINE DRUGS
12.1 List of Small Lymphocytic Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. SMALL LYMPHOCYTIC LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SMALL LYMPHOCYTIC LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SMALL LYMPHOCYTIC LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Small Lymphocytic Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Small Lymphocytic Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Small Lymphocytic Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Small Lymphocytic Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Small Lymphocytic Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Small Lymphocytic Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Small Lymphocytic Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Small Lymphocytic Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
16 SMALL LYMPHOCYTIC LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SMALL LYMPHOCYTIC LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SMALL LYMPHOCYTIC LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 SMALL LYMPHOCYTIC LYMPHOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 SMALL LYMPHOCYTIC LYMPHOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 SMALL LYMPHOCYTIC LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 SMALL LYMPHOCYTIC LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 SMALL LYMPHOCYTIC LYMPHOMA - UNMET NEEDS
10 SMALL LYMPHOCYTIC LYMPHOMA - KEY ENDPOINTS OF TREATMENT
11 SMALL LYMPHOCYTIC LYMPHOMA - MARKETED PRODUCTS
11.1 List of Small Lymphocytic Lymphoma Marketed Drugs Across the Top 7 Markets
11.1.1 Imbruvica (Ibrutinib) - Janssen/Pharmacyclics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Calquence (Acalabrutinib) - Acerta Pharma/AstraZeneca
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Copiktra (Duvelisib) - Secura Bio
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Venclexta (Venetoclax) - AbbVie/Genentech
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Zydelig (Idelalisib) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 SMALL LYMPHOCYTIC LYMPHOMA - PIPELINE DRUGS
12.1 List of Small Lymphocytic Lymphoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. SMALL LYMPHOCYTIC LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. SMALL LYMPHOCYTIC LYMPHOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 SMALL LYMPHOCYTIC LYMPHOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Small Lymphocytic Lymphoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Small Lymphocytic Lymphoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Small Lymphocytic Lymphoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Small Lymphocytic Lymphoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Small Lymphocytic Lymphoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Small Lymphocytic Lymphoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Small Lymphocytic Lymphoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Small Lymphocytic Lymphoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Small Lymphocytic Lymphoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Small Lymphocytic Lymphoma - Access and Reimbursement Overview
16 SMALL LYMPHOCYTIC LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 SMALL LYMPHOCYTIC LYMPHOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 SMALL LYMPHOCYTIC LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
